Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert M. Jotte, of the Rocky Mountain Cancer Center in Denver, Colorado.

The primary objective of this study is to compare the efficacy of the standard of care for this patient population to the standard of care in combination with AEG35156. Recruitment for this trial is expected to be completed prior to the end of 2009.

"Preliminary evidence of activity was observed in the Phase 1 portion of this study and encouraged us to amend the clinical protocol to provide for a control arm for the Phase 2 portion of the study" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

"Our clinical program around AEG35156 continues to accelerate and expand as we seek to move this therapeutic forward to more advanced stages of clinical development," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "The initiation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in AML at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to announce over the course of 2009."

About AEG35156

Cancer cells acquire multiple mutations that disable their normal response to apoptotic triggers. AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel drug target for the development of anti-cancer therapeutics.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera has two additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 21, 2017 , ... Building on the success of the inaugural ... on the very latest developments in radical life extension. RAADfest combines cutting edge science ... the empowerment of personal development, making it the largest most comprehensive and inclusive super ...
(Date:6/22/2017)... CA (PRWEB) , ... June 22, 2017 , ... ... global health leaders in designating infertility as a disease, bringing new hope for ... week at their 2017 annual meeting to back the World Health Organization’s designation ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... and life sciences industries, continue to be in demand for their insights and ... be speaking on “The State of Information Governance in the Biopharmaceutical Industry” at ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... the release of Limfinity® version 6.5, a content-packed update to the Limfinity® framework. ... gain a larger and more diverse base of customers among labs and other ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):